Aptose Biosciences to Go Private in C$2.41 Per Share Arrangement
APTOF has more than doubled off its 52-week low of $0.636 on light trading volume (0.3× avg).
Summary
Aptose Biosciences Inc. is being acquired by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., in a going-private transaction for C$2.41 per common share, leading to its delisting.
Key Events · M&A and Partnerships · APTOF
-
Going Private Transaction Announced
Aptose Biosciences Inc. will be acquired by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., through a Plan of Arrangement.
-
Shareholders to Receive C$2.41 Per Share
Public shareholders will receive C$2.41 in cash for each common share, which translates to approximately $1.71 USD, representing a premium over the current trading price.
-
Delisting and Deregistration
Upon completion, Aptose Biosciences Inc. will become a wholly-owned subsidiary, cease to be a reporting issuer, and its shares will be delisted from the Toronto Stock Exchange and OTC Markets.
-
Board Recommends Approval
The company's Board of Directors, based on the recommendation of an independent special committee and a fairness opinion, unanimously approved and recommended the Arrangement to shareholders.
Analysis · APTOF · Life Sciences
This SC 13E3 filing confirms a definitive agreement for Aptose Biosciences Inc. to be acquired and taken private by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., for C$2.41 per common share. The transaction, valued at approximately $3.5 million, represents a significant premium to the current stock price and will result in the company's common shares being delisted from public exchanges. While existing shareholders will receive cash consideration at a premium, the event marks the end of Aptose Biosciences as a publicly traded entity, fundamentally altering its investment profile and removing it from the public market.
At the time of this filing, APTOF was trading at $1.57 on OTC in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $0.64 to $350.55. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.